Firstly, through a systematic review and network meta-analysis, researchers have assessed the effects of GLP-1R agonists on neuroinflammation and reported that, compared with placebo, GLP-1R agonists significantly reduce the levels of neuroinflammatory markers, such as TNF- and interleukin-1 (Urkon et al., 2025
Q5: What is the Medicare WISeR model and which states does it affect
The company is optimistic about the market growth despite the price impact
The Medicare GLP-1 Bridge program will cover three prescription weight loss medications: Fundayo Wegovy injection or tablet Zepbound Kwikpen (single-dose pens and vials are not covered) Medicare and Medicaid will not cover other GLP-1s for weight loss
As an important part of your immune and endocrine system, we are able to balance, fine-tune and, if needed, boost its function through our personalized treatment plans